Division: Pharmacy Policy	Subject: State of Florida's Agency for Health Care Administration's Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	June 7, 2012 November 19, 2015

Neupro®(rotigotine transdermal system)

LENGTH OF AUTHORIZATION: Up to one year

REVIEW CRITERIA:

- Patient must be ≥18 years of age.
- Must have a confirmed diagnosis (in medical records or diagnosis codes) of Parkinson's disease or Restless Legs Syndrome.
- In the case of Parkinson's disease, the patient must have a minimum of a 60 day trial of at least three other dopamine agonists [ropinirole (Requip®), pramipexole (Mirapex®), selegiline (Eldepryl®, Zelapar®), carbidopa/levodopa (Sinemet®, Parcopa®)]
- In the case of Restless Legs Syndrome, the patient must have a minimum of a 60 day trial of at least three other agents [ropinirole, pramipexole, carbidopa/levodopa, gabapentin (Neurontin®)]

DOSING and ADMINISTRATION:

- Apply once a day to the skin; press firmly in place for 30 seconds, making good contact. Do not place Neupro on oily, irritated, or damaged skin, or where it will be rubbed by tight clothing. Do not use the same site more than once every 14 days. The prescribed dose may be achieved using single or multiple patches.
    - **Parkinson's disease:** Initially, 2 mg/24 hours for early-stage disease or 4 mg/24 hours for advanced-stage disease. The dose may be increased as needed by 2 mg/24 hours at weekly intervals, up to 6 mg /24 hours for early-stage disease and up to 8 mg/24 hours for advanced-stage disease.
    - **Restless Legs Syndrome:** Initially, 1 mg/24 hours, increased as needed by 1 mg/24 hours at weekly intervals, up to 3 mg/24 hours.
- To discontinue treatment, reduce the dose gradually until complete withdrawal of Neupro.
- **Dosage form**: Transdermal System: 1 mg, 2 mg, 3 mg, 4 mg, 6 mg and 8 mg rotigotine per 24 hours